V
Vincent T.H.B.M. Smit
Researcher at Leiden University Medical Center
Publications - 163
Citations - 11210
Vincent T.H.B.M. Smit is an academic researcher from Leiden University Medical Center. The author has contributed to research in topics: Breast cancer & Endometrial cancer. The author has an hindex of 50, co-authored 147 publications receiving 8598 citations. Previous affiliations of Vincent T.H.B.M. Smit include Loyola University Medical Center & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas.
Vincent T.H.B.M. Smit,Angelina J.M. Boot,A M Smits,Gert Jan Fleuren,Cees J. Cornelisse,Johannes L. Bos +5 more
TL;DR: DNAs from human pancreatic adenocarcinomas were analyzed for the presence of mutations in codons 12, 13 and 61 of the NRAS, KRAS and HRAS gene and found a mutation in codon 12 of the KRAS gene, confirming the findings of Almoguera et al.
Journal ArticleDOI
Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts
Ellen Stelloo,Remi A. Nout,Elisabeth M. Osse,Ina J. Jürgenliemk-Schulz,Jan J. Jobsen,Ludy C.H.W. Lutgens,Elzbieta van der Steen-Banasik,Hans W. Nijman,Hein Putter,Tjalling Bosse,Carien L. Creutzberg,Vincent T.H.B.M. Smit +11 more
TL;DR: Assessment of this integrated risk profile is feasible in daily practice, and holds promise to reduce both overtreatment and undertreatment, in patients with early-stage endometrial carcinoma.
Journal ArticleDOI
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Dionyssios Katsaros,Paul Bessette,Christine Haie-Meder,Petronella B. Ottevanger,Jonathan A. Ledermann,Pearly Khaw,Alessandro Colombo,Anthony Fyles,Marie Helene Baron,Ina M. Jürgenliemk-Schulz,Henry C Kitchener,Hans W. Nijman,G. Wilson,Susan Brooks,Silvestro Carinelli,Diane Provencher,Chantal Hanzen,Ludy C.H.W. Lutgens,Vincent T.H.B.M. Smit,Naveena Singh,V. Do,Romerai D'Amico,Remi A. Nout,Amanda Feeney,Karen W Verhoeven-Adema,Hein Putter,Carien L. Creutzberg,Mary McCormack,Karen Whitmarsh,Rozenn Allerton,Deborah Gregory,P. Symonds,Peter Hoskin,Madhavi Adusumalli,Anjana Anand,Robert Wade,Alexandra J. Stewart,Wendy Taylor,Roy F.P.M. Kruitwagen,Harry Hollema,Elizabeth Pras,An Snyers,Lukas J.A. Stalpers,Jan J. Jobsen,Annerie Slot,Jan Willem M. Mens,Tanja C. Stam,Baukelien Van Triest,Elzbieta M. Van der Steen Banasik,Karin A.J. De Winter,Michael A. Quinn,Ilka Kolodziej,Jan Pyman,Carol Johnson,Anne Capp,Roldano Fossati,Sergio Gribaudo,Andrea Lissoni,Annamaria Ferrero,Grazia Artioli,Cathy Davidson,C. Meg McLachlin,Prafull Ghatage,Paula V.C. Rittenberg,Luis Souhami,Gillian Thomas,Pierre Duvillard,Dominique Berton-Rigaud,Nicole Tubiana-Mathieu +71 more
TL;DR: Adjuvant chemotherapy given during and after radiotherapy for high-risk endometrial cancer did not improve 5-year overall survival, although it did increase failure-free survival.
Journal ArticleDOI
Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
Alicia Leon-Castillo,Stephanie M. de Boer,Melanie E Powell,Linda Mileshkin,Helen Mackay,Alexandra Leary,Hans W. Nijman,Hans W. Nijman,Naveena Singh,Pamela M. Pollock,Paul Bessette,Anthony Fyles,Christine Haie-Meder,Vincent T.H.B.M. Smit,Richard J. Edmondson,Hein Putter,Henry C Kitchener,Emma J Crosbie,Marco de Bruyn,Remi A. Nout,Nanda Horeweg,Carien L. Creutzberg,Tjalling Bosse +22 more
TL;DR: Molecular classification has strong prognostic value in high-risk EC, with significantly improved RFS with adjuvant CTRT for p53abn tumors, regardless of histologic type.
Journal ArticleDOI
Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative.
Ellen Stelloo,Tjalling Bosse,Remi A. Nout,Helen Mackay,David N. Church,Hans W. Nijman,Alexandra Leary,Richard J. Edmondson,Melanie E Powell,Emma J Crosbie,Henry C Kitchener,Linda Mileshkin,Pamela M. Pollock,Vincent T.H.B.M. Smit,Carien L. Creutzberg +14 more
TL;DR: In this article, the authors investigated whether molecular analysis can be used to refine risk assessment, direct adjuvant therapy, and identify actionable alterations in high-risk endometrial cancer.